Matches in SemOpenAlex for { <https://semopenalex.org/work/W4287188801> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W4287188801 abstract "Canakinumab is an interleukin (IL)-1β inhibitory antibody. Recently, a large trial of canakinumab in cardiac patients described lower lung cancer incidence in patients treated with canakinumab compared to controls. This finding is the basis for ongoing clinical trials of canakinumab in lung cancer. To address the underlying mechanism, we established lung cancer co-cultures to investigate the interactions between lung cancer cells and immunocyte macrophages as related to the expression of IL-1β and the effect of IL-1β on the NF-κB pathway on lung cancer cells.Lung cancer cell lines H838 and H1975 and macrophages were mono-cultured separately as control groups. Lung cancer cell lines and macrophages were co-cultured respectively in a ratio of 5:1 under the conditions of 37°C in a humidified atmosphere of 5% CO2 for seven days. Cell culture supernatants were collected at predetermined time points, and cell morphology was observed and photographed by microscopy. IL-1β was detected by ELISA. H838 and H1975 cells were treated with PBS or IL-1β for 24 hours. Cells were harvested and lysed, then analyzed in a proteome profiler array.Cells in co-cultures initially grew well. IL-1β was almost undetectable in lung cancer cell lines and macrophage monoculture groups but was highly expressed in co-cultures after 24h and declined at the 7th day. In the H838 and H1975 co-culture group, the lung cancer cells occupied a great majority. IL-1β activates the NF-κB pathway on H838 and H1975 cells.Our data showed that in a lung cancer co-culture incorporating lung cancer cells and macrophages lead to a higher expression of IL-1β than monoculture. It is possible that such dynamic changes in IL-1β expression may also occur in vivo in response to changes in the tumor microenvironment and interactions with immune cell populations. These interactions are likely important components to be considered when studying and modeling the expression of IL-1β as a potential therapeutic target in lung cancer." @default.
- W4287188801 created "2022-07-25" @default.
- W4287188801 creator A5000250168 @default.
- W4287188801 creator A5002096737 @default.
- W4287188801 creator A5018234513 @default.
- W4287188801 creator A5054440679 @default.
- W4287188801 creator A5056036725 @default.
- W4287188801 creator A5076699095 @default.
- W4287188801 date "2021-05-01" @default.
- W4287188801 modified "2023-09-26" @default.
- W4287188801 title "Effects of the NF-κB Pathway Agonist IL-1β on Non-Small Cell Lung Cancer Cell Lines." @default.
- W4287188801 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34162558" @default.
- W4287188801 hasPublicationYear "2021" @default.
- W4287188801 type Work @default.
- W4287188801 citedByCount "0" @default.
- W4287188801 crossrefType "journal-article" @default.
- W4287188801 hasAuthorship W4287188801A5000250168 @default.
- W4287188801 hasAuthorship W4287188801A5002096737 @default.
- W4287188801 hasAuthorship W4287188801A5018234513 @default.
- W4287188801 hasAuthorship W4287188801A5054440679 @default.
- W4287188801 hasAuthorship W4287188801A5056036725 @default.
- W4287188801 hasAuthorship W4287188801A5076699095 @default.
- W4287188801 hasConcept C121608353 @default.
- W4287188801 hasConcept C126322002 @default.
- W4287188801 hasConcept C142724271 @default.
- W4287188801 hasConcept C153911025 @default.
- W4287188801 hasConcept C203014093 @default.
- W4287188801 hasConcept C2776256026 @default.
- W4287188801 hasConcept C2779134260 @default.
- W4287188801 hasConcept C2779725882 @default.
- W4287188801 hasConcept C2781228260 @default.
- W4287188801 hasConcept C502942594 @default.
- W4287188801 hasConcept C54355233 @default.
- W4287188801 hasConcept C71924100 @default.
- W4287188801 hasConcept C81885089 @default.
- W4287188801 hasConcept C86803240 @default.
- W4287188801 hasConcept C96232424 @default.
- W4287188801 hasConceptScore W4287188801C121608353 @default.
- W4287188801 hasConceptScore W4287188801C126322002 @default.
- W4287188801 hasConceptScore W4287188801C142724271 @default.
- W4287188801 hasConceptScore W4287188801C153911025 @default.
- W4287188801 hasConceptScore W4287188801C203014093 @default.
- W4287188801 hasConceptScore W4287188801C2776256026 @default.
- W4287188801 hasConceptScore W4287188801C2779134260 @default.
- W4287188801 hasConceptScore W4287188801C2779725882 @default.
- W4287188801 hasConceptScore W4287188801C2781228260 @default.
- W4287188801 hasConceptScore W4287188801C502942594 @default.
- W4287188801 hasConceptScore W4287188801C54355233 @default.
- W4287188801 hasConceptScore W4287188801C71924100 @default.
- W4287188801 hasConceptScore W4287188801C81885089 @default.
- W4287188801 hasConceptScore W4287188801C86803240 @default.
- W4287188801 hasConceptScore W4287188801C96232424 @default.
- W4287188801 hasLocation W42871888011 @default.
- W4287188801 hasOpenAccess W4287188801 @default.
- W4287188801 hasPrimaryLocation W42871888011 @default.
- W4287188801 hasRelatedWork W11877123 @default.
- W4287188801 hasRelatedWork W1264489 @default.
- W4287188801 hasRelatedWork W12785845 @default.
- W4287188801 hasRelatedWork W14537455 @default.
- W4287188801 hasRelatedWork W14687542 @default.
- W4287188801 hasRelatedWork W17235185 @default.
- W4287188801 hasRelatedWork W18766104 @default.
- W4287188801 hasRelatedWork W19370465 @default.
- W4287188801 hasRelatedWork W9265739 @default.
- W4287188801 hasRelatedWork W9430694 @default.
- W4287188801 isParatext "false" @default.
- W4287188801 isRetracted "false" @default.
- W4287188801 workType "article" @default.